Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes
Key result
SGLT2 inhibitors are being evaluated for blood pressure reduction in type 2 diabetes, with previous reviews demonstrating a 4-10 mmHg reduction in systolic blood pressure.
Why the study?
Does empagliflozin reduce blood pressure in subjects with type 2 diabetes?
Population
Over 800 subjects with type 2 diabetes, mean age 60 years, mean eGFR 84 mL/min/1.73 m2, normotensive or…
Design
Editorial, randomized
Authors
Discussion
Loading...
Member takes
Implication
This editorial discusses a study investigating the blood pressure-lowering effects of empagliflozin in patients with type 2 diabetes.
Structured PICO
Does empagliflozin reduce blood pressure in subjects with type 2 diabetes?
P
Population
Over 800 subjects with type 2 diabetes, mean age 60 years, good kidney function, and normotension or stage 1 hypertension.
I
Intervention
Empagliflozin 10 mg daily or empagliflozin 25 mg daily
O
Outcome
Blood pressure using 24-h ambulatory blood pressure monitoringsurrogate
This editorial discusses a study investigating the blood pressure-lowering effects of empagliflozin in patients with type 2 diabetes.
Cite This Study
Majewski et al. (2015) conducted an editorial in Type 2 diabetes (n=800). Empagliflozin was evaluated on Blood pressure using 24-h ambulatory blood pressure monitoring. SGLT2 inhibitors are being evaluated for blood pressure reduction in type 2 diabetes, with previous reviews demonstrating a 4-10 mmHg reduction in systolic blood pressure.